EMA Authorised: Nilotinib Accord (nilotinib) — Accord Healthcare S.L.U.

View source ↗

Summary

Accord Healthcare S.L.U. has been authorised to market Nilotinib Accord for chronic myeloid leukemia that is BCR-ABL positive.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib Accord (nilotinib)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myelogenous, Chronic, BCR-ABL Positive. MAH: Accord Healthcare S.L.U.. Decision date: 26/08/2025